title: HIV infection and host genetic mutation among injecting drug-users of northeastern states of India.
abstract: A community-based cross-sectional study was conducted among injecting drug-users (IDUs) of the northeastern states of India to understand the host genetic factors that confer resistance to HIV infection. The study aimed at assessing the existence and magnitude of genetic mutations of chemokine receptors, such as CCR2-64I, CCR-5 D-32, and SDF-1-3'A, that are known to confer resistance to HIV infection and progression of disease in some set-ups. In total, 711 IDUs from Manipur, Mizoram, Nagaland, and Meghalaya were sampled for the study. The selected participants were interviewed to study their sociodemography, risk behaviours, and risk perceptions after obtaining their verbal informed consent. The interview was followed by collection of about 5 mL of blood samples by an unlinked anonymous method for studying genetic mutation and HIV infection. All the blood samples were transported to and processed at the clinical medicine laboratory of the National Institute of Cholera & Enteric Diseases, Kolkata, India. The genetic mutations were detected by polymerase chain reaction (PCR) and the restriction fragment length polymorphism (RFLP) assay techniques. The study revealed that 328 (46.1%) IDUs were aged 20-29 years, 305 (42.9%) were aged 30-39 years, and only two (0.3%) were aged above 49 years. The rate of HIV seropositivity varied widely among the IDUs living in different northeastern states that ranged from 4.5% to 61%. There was not a single IDU with CCR5 homozygous mutation. Mutated genes of CCR2-64I and SDF-1-3'A were detected in the frequencies of 49% and 23% respectively in them. The rate of HIV seropositivity in IDUs having CCR2 mutant gene was 27% (n=94) and without mutation was 27% (n=98). Similarly, HIV seropositivity in IDUs with and without SDF1 mutation was 28% (n=46) and 27% (n=146) respectively. Both the differences were not statistically significant. A CCR5 homozygous mutation is known to be the most prominent marker that confers resistance against HIV infection. The absence of CCRS mutant gene in this population suggests that they do not have any additional protection against HIV infection. Analysis also revealed that, although mutation of CCR2 and SDF1 was present in this population, it did not confer any additional resistance against HIV. This indicates that the IDUs of northeastern India are not additionally protected against HIV infection through genetic mutation and are, therefore, vulnerable to acquire HIV infection due to high-risk behaviour and other related factors.
authors.affiliation: Division of Epidemiology [HIV/AIDS], National Institute of Cholera & Enteric Diseases P-33 CIT Road, Scheme XM Kolkata 700 010, India. kamalesh.sarkar@gmail.com
authors.forename: Kamalesh
authors.initials: K
authors.lastname: Sarkar
authors.forename: Santa Sabuj
authors.initials: SS
authors.lastname: Das
authors.forename: Reshmi
authors.initials: R
authors.lastname: Pal
authors.forename: Baishali
authors.initials: B
authors.lastname: Bal
authors.forename: P
authors.initials: P
authors.lastname: Madhusudan
authors.forename: Sekhar
authors.initials: S
authors.lastname: Chakraborti
mesh_terms: D000328:Adult; D017677:Age Distribution; D054377:Chemokine CXCL12 / Q000235:genetics; D003430:Cross-Sectional Studies; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000453:epidemiology* / Q000235:genetics*; D006801:Humans; D007194:India / Q000453:epidemiology; D008297:Male; D009154:Mutation / Q000235:genetics*; D016485:Needle Sharing / Q000706:statistics & numerical data; D016017:Odds Ratio; D016133:Polymerase Chain Reaction / Q000379:methods; D012150:Polymorphism, Restriction Fragment Length / Q000235:genetics; D054390:Receptors, CCR2 / Q000235:genetics; D019707:Receptors, Chemokine / Q000235:genetics; D015819:Substance Abuse, Intravenous / Q000097:blood / Q000453:epidemiology*; D055815:Young Adult
chemical_list: C515334:CCR2 protein, human; D054377:Chemokine CXCL12; D054390:Receptors, CCR2; D019707:Receptors, Chemokine
references.citation: Natl Med J India. 2001 Jul-Aug;14(4):209-11
references.pmid: 11547526
references.citation: Br Med Bull. 2001;58:7-18
references.pmid: 11714621
references.citation: J Commun Dis. 1999 Mar;31(1):23-8
references.pmid: 10810582
references.citation: J Med Virol. 1999 May;58(1):54-8
references.pmid: 10223546
references.citation: BMC Public Health. 2006 Oct 10;6:248
references.pmid: 17029648
references.citation: Science. 1996 Sep 27;273(5283):1856-62
references.pmid: 8791590
references.citation: Bull Narc. 1993;45(1):91-105
references.pmid: 8305909
references.citation: Vaccine. 2008 Jun 6;26(24):2966-80
references.pmid: 18321617
references.citation: Eur J Hum Genet. 2000 Dec;8(12):975-9
references.pmid: 11175286
references.citation: J Urban Health. 2006 Jan;83(1):5-17
references.pmid: 16736351
references.citation: J Acquir Immune Defic Syndr. 2001 Aug 15;27(5):472-81
references.pmid: 11511825
references.citation: AIDS. 2000 Jan 7;14(1):75-83
references.pmid: 10714570
references.citation: Arch Intern Med. 2001 May 28;161(10):1281-8
references.pmid: 11371255
references.citation: J Acquir Immune Defic Syndr. 2004 Apr 15;35(5):503-10
references.pmid: 15021315
references.citation: Harv AIDS Rev. 1998 Fall;:1
references.pmid: 12294441
references.citation: Science. 1998 Jan 16;279(5349):389-93
references.pmid: 9430590
references.citation: Science. 1997 Aug 15;277(5328):959-65
references.pmid: 9252328
references.citation: Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5199-204
references.pmid: 11320252
references.citation: Am J Hum Genet. 1999 Oct;65(4):1047-53
references.pmid: 10486323
references.citation: J Psychoactive Drugs. 2006 Sep;38(3):305-10
references.pmid: 17165373
references.citation: Int J STD AIDS. 2003 Nov;14(11):762-4
references.pmid: 14624740
references.citation: Indian J Public Health. 1997 Apr-Jun;41(2):49-51
references.pmid: 9988977
references.citation: Subst Use Misuse. 2006;41(3):341-52
references.pmid: 16467010
references.citation: Rev Invest Clin. 2004 Mar-Apr;56(2):134-42
references.pmid: 15377067
references.citation: Harm Reduct J. 2008 Aug 25;5:29
references.pmid: 18724872
references.citation: J Infect Dis. 2006 Jan 1;193(1):16-26
references.pmid: 16323127
references.citation: PLoS One. 2008 Jul 23;3(7):e2747
references.pmid: 18648518
references.citation: AIDS Care. 2009 Jan;21(1):31-41
references.pmid: 19085218
references.citation: AIDS Care. 2000 Aug;12(4):497-504
references.pmid: 11091782